Carvedilol Is Non‑Dialyzable and Does Not Require Dose Adjustment in Hemodialysis Patients

Dialyzability Evidence

The EXTRIP workgroup classified carvedilol as non‑dialyzable, with approximately 0 % of the ingested dose recovered in dialysate during hemodialysis, indicating negligible removal by the procedure. 1
Pharmacokinetic studies in patients with end‑stage renal disease demonstrated no difference in carvedilol plasma concentrations between dialysis and non‑dialysis days, confirming the lack of dialytic clearance. 1

No dose adjustment or supplemental dosing is required for carvedilol in individuals receiving hemodialysis; the drug can be administered on both dialysis and non‑dialysis days without timing considerations related to the dialysis session. 1

The K/DOQI (Kidney Disease Outcomes Quality Initiative) guidelines recommend carvedilol as the preferred beta‑blocker for dialysis patients with severe dilated cardiomyopathy, citing evidence of reduced cardiovascular deaths and total mortality. (Guideline strength: strong recommendation based on observational outcome data.) 2
In patients with stable intradialytic blood pressure and dilated cardiomyopathy, carvedilol is preferred because it provides a consistent therapeutic effect without the need for post‑dialysis dosing. (Evidence level: moderate, derived from guideline consensus and cohort studies.) 2

For patients who experience frequent intradialytic hypotension, carvedilol (and other non‑dialyzable beta‑blockers) should be avoided, as its persistent effect during dialysis can increase the risk of hypotension when combined with ultrafiltration. (Evidence level: low to moderate; based on retrospective observations.) 2

Carvedilol is classified as "not dialyzable" according to the EXTRIP workgroup's systematic review and recommendations 3
When measured from dialysate collection during hemodialysis, the amount of carvedilol removed was approximately 0% of the ingested dose 3

Unlike carvedilol, other beta-blockers such as atenolol, metoprolol, and bisoprolol are significantly removed by dialysis 3
This difference in dialyzability may have clinical implications for blood pressure control and cardiovascular protection during dialysis 4, 5

When selecting beta-blockers for dialysis patients, consider that non-dialyzable agents like carvedilol maintain their therapeutic effect throughout dialysis 4, 5
However, some retrospective studies suggest higher mortality rates with non-dialyzable carvedilol versus dialyzable metoprolol, possibly due to increased risk of intradialytic hypotension 4, 5
For patients with frequent intradialytic hypotension, it may be prudent to avoid non-dialyzable medications like carvedilol 5
For patients with stable intradialytic blood pressure, carvedilol's longer-acting properties may improve adherence and reduce pill burden 5

The timing of carvedilol administration should be individualized based on interdialytic blood pressure patterns and frequency of intradialytic hypotension 5